Aussie Peptides · AU
Tirzepatide 15mg
$219.00
Why Aussie Peptides
Lot-matched certificate
Independently analysed before release; look the lot up on the verification page.
Strictly research use
Not for human or veterinary consumption.
Express AU shipping
Discreet, fully tracked, 1–3 business days.
Aussie Peptides · specification
Tirzepatide 15mg
- Presentation
- 15mg sealed glass vial
- SKU
- TIRZEPATIDE-15MG
- Format
- Lyophilised powder
- Purity
- ≥99% release specification by RP-HPLC — result recorded per lot
- Documentation
- Batch-specific Certificate of Analysis
- Storage
- 2–8 °C, protect from light
- Dispatch
- Cold-chain, same-day, Australia-wide
- Origin
- Packed in Australia · Aussie Peptides
- Category
- Metabolic
Specifications are standardised across the Aussie Peptides range. Batch values — lot number, assay result and expiry — are printed on the vial and matched to the Certificate of Analysis supplied with your order.
The Aussie Peptides label
- 1
Coral spine + hexagon mark
Every Aussie Peptides vial carries the same coral spine and molecular hexagon so a genuine vial is recognisable at a glance.
- 2
Compound, strength, fill volume
Printed in a fixed position on the cream label — compound name, strength in milligrams, and vial volume.
- 3
LOT + EXP fields
Hand-stamped per batch and matched to the Certificate of Analysis you can look up on our CoA page.
- 4
Lot-tested by RP-HPLC — research use only
The compliance line appears on every label, on every SKU, without exception.
Tirzepatide — strengths
Same batch-tested material, different presentations. Higher-strength vials lower the cost per milligram; blends arrive pre-combined in a single lyophilised cake so one reconstitution covers both compounds.
Laboratory handling · Metabolic research peptide
Usage & handling guide
A lyophilised peptide with a long solution half-life. Reconstitute gently, aliquot immediately, and keep cold at all times.
- Reconstitution
- 3 mL bacteriostatic or sterile water for a standard bench stock
- Stock concentration
- ≈ 5.0 mg/mL (15 mg ÷ 3 mL)
- Storage once reconstituted
- 2–8 °C, upright, protected from light
- Stability window
- Use reconstituted stock within 21–28 days at 2–8 °C; freeze single-use aliquots at −20 °C for longer holds
1 · Equilibrate before opening
Let the sealed vial reach room temperature before breaking the seal. Opening a cold vial draws in moisture, and lyophilised peptide is hygroscopic.
2 · Add diluent down the wall
Direct the diluent slowly against the inside wall of the vial rather than onto the powder cake. A fast stream shears the peptide and lowers recovery.
3 · Dissolve, never shake
Swirl or roll gently until the cake is fully dissolved. Vortexing or shaking foams the solution and denatures peptide at the air–liquid interface.
4 · Inspect the solution
A correctly reconstituted stock is clear and free of visible particulate. Cloudiness, fibres, or a film indicates the stock should be discarded.
5 · Aliquot for single use
Split the stock into single-use aliquots in low-bind tubes and label each with compound, concentration, LOT and date. Repeated freeze–thaw is the most common cause of lost potency.
6 · Record against the CoA
Log the LOT number and the batch Certificate of Analysis reference alongside your results so every data point is traceable to a tested batch.
Figures above are worked examples for bench preparation only. Always calculate your own working concentrations from the strength printed on the vial, the exact diluent volume you added, and the batch assay result on the Certificate of Analysis.
Safety & handling cautions
- Do not freeze the reconstituted stock repeatedly — one freeze–thaw per aliquot only.
- Keep the vial upright; product retained in the stopper is lost mass and skews your calculated concentration.
- Wear appropriate PPE, work in a clean and controlled area, and dispose of vials, sharps and unused stock in line with your institution’s waste procedures.
Important — no dosage advice
This guide covers reconstitution, storage and laboratory handling only. Aussie Peptides does not publish, supply or advise on human or veterinary dosing, administration schedules, or therapeutic protocols for any product, and nothing here should be interpreted as such.
All products are supplied strictly for in-vitro laboratory research by qualified professionals. They are not medicines, are not evaluated by the TGA, and are not for human or animal consumption. Nothing on this page is medical advice — speak to a qualified healthcare professional about any health matter.
In depth
Tirzepatide in Australia — research notes
Tirzepatide 15mg is the mid-size research vial of the dual GIP/GLP-1 receptor agonist, sitting between the 10mg and 20mg presentations for Australian metabolic laboratories.
- 15mg lyophilised dual GIP/GLP-1 agonist
- 3mL diluent gives 5mg/mL
- Strengths stocked: 10, 15, 20 and 30mg
Dual incretin receptor activity
Tirzepatide engages both the GIP and GLP-1 receptors, which is what separates it from single-agonist analogues such as semaglutide. Comparative metabolic studies typically run all three incretin classes side by side.
Concentration arithmetic
15mg with 3mL of bacteriostatic water gives 5mg/mL; with 1.5mL it gives 10mg/mL. Choose the volume that lets your syringe graduations land on whole marks for the draw size the protocol calls for.
Choosing a strength
10mg suits short pilot work, 15mg and 20mg extended runs, and 30mg gives the lowest cost per milligram for long studies. Every vial ships from our Australian storage and dispatch facility with a lot-matched certificate of analysis and cold-chain packaging.
About this compound
Research overview
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide, supplied as a 15mg lyophilised research vial. HPLC verified to >=99% purity with a lot-matched certificate of analysis. Laboratory research use only.
Compliance
For in‑vitro research only.
Products supplied for laboratory research. Not for human or veterinary consumption. Buyer assumes all responsibility.
Read compliance →Questions
Tirzepatide 15mg — frequently asked
What is Tirzepatide?+
Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide, supplied as a 15mg lyophilised research vial. HPLC verified to >=99% purity with a lot-matched certificate of analysis. Aussie Peptides supplies Tirzepatide strictly as an in-vitro laboratory reference material — it is not a therapeutic good and is not for human or veterinary use.
How pure is Aussie Peptides Tirzepatide?+
Each Tirzepatide lot is analysed by RP-HPLC for purity and by mass spectrometry for identity, and is released against a ≥99% purity specification. The result belongs to that lot: the number printed on your vial maps to its own Certificate of Analysis, so the figure can be recorded alongside your experimental data rather than assumed.
How is Tirzepatide 15mg reconstituted and stored in the lab?+
3 mL bacteriostatic or sterile water for a standard bench stock That gives a working stock of roughly ≈ 5.0 mg/mL (15 mg ÷ 3 mL). Reconstituted vials are held at 2–8 °c, upright, protected from light, and use reconstituted stock within 21–28 days at 2–8 °c; freeze single-use aliquots at −20 °c for longer holds Sealed lyophilised 15mg vials are stable long-term at -20°C.
Is it legal to buy Tirzepatide in Australia?+
Tirzepatide is supplied in Australia for in-vitro laboratory research only. It is not approved by the TGA as a therapeutic good and is not sold for human or veterinary consumption. Purchasers must be 18 or over and are responsible for handling, storage and disposal under their own institutional and legal requirements.
How much is Tirzepatide 15mg and how fast does it ship?+
Tirzepatide 15mg is $219.00. It is in stock and dispatched same business day on orders placed before 12pm AEST. Shipping is A$12.95 express Australia-wide and free over A$199, sent discreetly packaged and fully tracked, typically 1–3 business days.
What does the research on Tirzepatide investigate?+
Published work on this class focuses on incretin receptor signalling — GLP-1, GIP and glucagon pathways — in cell and animal models. Nothing on this page is a dosing protocol, medical advice, or a claim of therapeutic benefit — it summarises what the published literature examines.
Keep exploring
